Delamanid treatment for tuberculosis

Delamanid(Delamanid) is a promising nitrodihydroimidazole derivative for the treatment of multidrug-resistant tuberculosis. Delamanidinhibits the synthesis of methoxy and ketomycolic acids(components of the cell wall of Mycobacterium tuberculosis) through the F420coenzyme mycobacterial system, while producing nitrous oxide.

Delamanid(Delamanid)Adults (18 to64 years)The recommended dose is 100mg twice daily for 24 weeks. Older adults(> 65 years old):There are no data on older adults. Delamanidshould be taken with food. Delamanid(Delamanid)The treatment of tuberculosis needs to be taken continuously for 6 months.

The oral bioavailability of delamanidin humans is estimated to be 25%–47% and is significantly increased with a high-fat meal. Delamanid is highly protein bound (99.5%) which helps provide a long half-life of 30-38 hours.

Delamanid(Delamanid), also known asOPC67683, belongs to the nitroimidazole class. It is said to be drug-sensitive and drug-resistant Mtb and chemically (R)-2-methyl-6-Nitro-2-((4-(4-(4-(4-(Trifluoromethoxy)< /span>Phenoxy)Piperidine-1-yl)< /span>Phenoxy)Methyl)-2, 3-Dihydroimidazo[2, 1-b]oxazole has excellent in vitro and in vivo effects. Since delamanid is primarily protein-bound, its metabolism is primarily mediated by plasma albumin. To a lesser extent, the liver enzymes CYP3A4, CYP1A1, CYP2D6, and CYP2E1 may also be involved. Delamanimetabolites have no effect on theseCYPenzymes in vitro at doses greater than those observed in human liver. There is an original research version in Russia, and each box is about 1 more than a thousand. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0

xa0